Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Appointed director
Appointed CFO
Director departure
Inv. presentation
Quarterly results
Consulting agrmnt
Alliqua BioMedical, Inc. (ADYX) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/17/2019 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of convertible promissory note issued to entities affiliated with Domain Associates LLC in December 2019"
11/14/2019 8-K Quarterly results
10/02/2019 8-K Quarterly results
08/14/2019 8-K Quarterly results
Docs: "Adynxx, Inc. Condensed Consolidated Statements of Operations Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Operating expenses Research and development $ 1,895 $ 583 $ 3,226 $ 1,269 General and administrative 1,454 598 2,317 1,292 Grant reimbursements - - Total operating expenses, net 2,245 1,181 4,345 2,561 Loss from operations Interest expense, net Other income , net - 60 60 Loss from continuing operations Loss from discontinued operations - - Net loss $ $ $ $ Net loss per basic and diluted share: Loss from continuing operations $ $ $ $ Loss from discontinued operations - - Net loss per basic and diluted share $ $ $ $ Weighted-average number of common shares outstanding - basic and diluted 5,358,882 4,569,742 4,966,491 4,569,742 Adynxx, Inc. Condensed Co..."
08/01/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Eq...
07/22/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/26/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Shareholder Letter, issued on June 26, 2019"
06/17/2019 8-K Termination of a Material Definitive Agreement
06/12/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
06/10/2019 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "Consent of BDO USA, LLP, Private Adynxx’s independent registered public accounting firm",
"Audited financial statements of Private Adynxx as of and for the years ended December 31, 2018 and 2017 and unaudited financial statements of Private Adynxx for the three months ended March 31, 2019 and 2018",
"Unaudited pro forma condensed combined balance sheet as of March 31, 2019 and unaudited combined condensed statement of operations for the year ended December 31, 2018 and the three months ended March 31, 2019"
05/31/2019 8-K Changes in Registrant's Certifying Accountant, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Letter from Marcum LLP to the Securities and Exchange Commission"
05/09/2019 8-K Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-B...
Docs: "Certificate of Amendment to Certificate of Incorporation to Effect the Name Change",
"Certificate of Amendment to Certificate of Incorporation to Effect the Reverse Stock Split",
"Form of Common Stock Certificate",
"Loan and Security Agreement, and as amended from time to time, by and among Adynxx, Inc. and Oxford Finance LLC",
"Form of promissory note issued to Oxford Finance LLC",
"Form of warrant issued to Oxford Finance LLC",
"Offer Letter, by and between Rick Orr and Adynxx, Inc",
"Offer Letter, by and between Donald Manning, M.D., Ph.D., and Adynxx, Inc",
"Offer Letter, by and between Julien Mamet, Ph.D. and Adynxx, Inc",
"Adynxx, Inc. 2010 Equity Incentive Plan Adopted by the Board of Directors: December 8, 2010 Approved by the Stockholders: December 8, 2010 Termination Date: December 7, 2020 1. General. Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees, Directors and Consultants. Available Stock Awards. The Plan provides for the grant of the following Stock Awards: Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock Awards, and Restricted Stock Unit Awards. Purpose. The Company, by means of the Plan, seeks to secure and retain the services of the group of persons eligible to receive Stock Awards as set forth in Section 1, to provide incentives for such persons to exert maximum efforts for the success of the Company and a..."
04/12/2019 8-K Quarterly results
04/09/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/14/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/11/2019 8-K Submission of Matters to a Vote of Security Holders
01/03/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Shareholder Letter, issued on January 3, 2019"
12/13/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "About Adynxx Adynxx is a clinical stage biopharmaceutical company focused on bringing to market novel, disease-modifying products for the treatment of pain and inflammation. Since its founding in 2007, Adynxx has worked to discover and develop transcription factor decoys to modify the course of pain. Adynxx’ s resulting pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain in a readily-identified group of patients with a greater risk of experiencing increased pain and elevated opioid use following surgery, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain. Both programs were discovered by Adynxx and are part of the AYX decoy technology platform. Adynxx plans to continue d..."
11/28/2018 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among AquaMed Technologies, Inc., TO Pharmaceuticals LLC and AQ TOP, LLC",
"Alliqua Biomedical to spin off and merge its Contract Manufacturing Business with TO Pharmaceuticals LLC to Create an Independent, Publicly Traded Company focused on Cannabinoid-Based Pharmaceutical Therapies"
11/13/2018 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Amendment No. 1, to the Agreement and Plan of Merger and Reorganization, by and among Alliqua BioMedical, Inc., Adynxx, Inc. and Embark Merger Sub Inc"
10/12/2018 8-K Quarterly results
06/26/2018 8-K Submission of Matters to a Vote of Security Holders
05/11/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "General Release and Severance Agreement, by and between Alliqua BioMedical, Inc. and Bradford Barton",
"General Release and Severance Agreement, by and between Alliqua BioMedical, Inc. and Pellegrino Pionati"
05/07/2018 8-K Asset disposition
Docs: "Alliqua BioMedical, Inc. Announces Closing Asset Sale to Celularity Inc."
04/30/2018 8-K Submission of Matters to a Vote of Security Holders
03/15/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amendment Agreement, by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, LP",
"Bridge Loan Note, by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, LP",
"General Release and Severance Agreement, by and between Alliqua BioMedical, Inc. and Brian Posner"
02/09/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Forbearance and Amendment Agreement, by and among Alliqua BioMedical, Inc., AquaMed Technologies, Inc. and Perceptive Credit Holdings, LP"
01/05/2018 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Asset Purchase Agreement, between Alliqua BioMedical, Inc. and Celularity Inc",
"Alliqua BioMedical, Inc. Announces Definitive Asset Purchase Agreement with Celularity, Inc. YARDLEY, PA., January 5, 2018 -- Alliqua BioMedical, Inc. , a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced a definitive agreement with Celularity, Inc. , under which Celularity will acquire all of the property, assets and rights relating to the Company’ s advanced biologic wound care business - including Biovance® amniotic membrane allograft and Interfyl® Human Connective Tissue Matrix - and the Company’ s UltraMist® Therapy System and other therapeutic ultrasound platform products for an aggregate cash consideration of $29.0 million. No debt or significant liabilities are being assumed by Celularity in the transaction. Alliqua BioMedical’ s ..."
12/08/2017 8-K Resignation/termination of a director
11/24/2017 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/09/2017 8-K Quarterly results
Docs: "Alliqua BioMedical, Inc. Reports Third Quarter of Fiscal Year 2017 Financial Results and Increases Fiscal Year 2017 Financial Outlook",
"Alliqua BioMedical, Inc. Engages Cowen to Assist in Evaluating Potential Strategic Alternatives YARDLEY, Pa., November 9, 2017 – Alliqua BioMedical, Inc. , a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced that it has engaged Cowen as its independent financial advisor to assist the Company in evaluating potential strategic alternatives. “The Board of Directors has decided to engage Cowen to comprehensively and systematically explore and review potential strategic alternatives. Importantly, this strategic process will not distract the organization from executing our strategic growth objectives and, in parallel, we will continue to evaluate all potential opportunities to improve the strength of our balance sheet. Our primary objective in ..."
10/05/2017 8-K Quarterly results
09/13/2017 8-K Quarterly results
09/05/2017 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy